Full-Time

Sr. Scientist / Principal Scientist

Product Development, Peptide Formulations

Posted on 3/16/2025

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Compensation Overview

$128.2k - $185.9kAnnually

+ Annual Bonus + Equity Incentive Program

Senior, Expert

Company Does Not Provide H1B Sponsorship

San Diego, CA, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • BA/BS degree in Chemistry, Biochemistry, Biology, Chemical Engineering, or related field and 8+ years of experience in the pharmaceutical industry in a chemistry, analytical, or characterization laboratory setting OR
  • Master's degree in Chemistry, Biochemistry, Biology, Chemical Engineering, or related field preferred and 6+ years of similar experience noted above OR
  • PharmD (preferred) and 4+ years of similar experience noted above
  • Experience with solid dosage form development from preformulation through validation, and preferably with solubility enhancement, modified release, and/or pediatric dosage forms
  • Experience with conventional solid oral dosage form manufacturing equipment including: mixers, blenders, mills, dry and wet granulators, fluid bed processors, encapsulators, tablet presses, film coaters, etc.
  • Managing preclinical/clinical Contract Research Organizations and Contract Manufacturing Organizations. Extensive experience preparing INDs & NDAs
  • Thorough understanding of principles and design of various peptide/protein formulations (small molecule parenteral and oral drug product development experience is a positive differentiator)
  • Good understanding of health authority regulations and guidelines for drug product development and approval processes
  • Knowledge in statistics and statistical thinking in formulation and process design and validation
  • Good knowledge in various drug product manufacturing processes
  • Good understanding of drug development and commercialization processes
  • Working knowledge in the following instrument/testing: HPLC (SEC-MALS), dissolution, Particle-Size Analysis, viscosity, dynamic light scattering (DLS), Capillary Isoelectric Focusing (cIEF), Subvisible particulate matter, density, osmolality
  • Working knowledge in applying QbD principles in drug product development
  • Technical writing: protocols, SOPs, and reports
  • Experience working at or with Contract Development and Manufacturing Organizations (CDMOs)
  • Assimilates data and research findings outside of Neurocrine for application to new scientific projects
  • Maintains broad knowledge of scientific principles and theories and possesses intellectual mastery of one or more scientific areas
  • May develop an understanding of other areas and related dependences
  • Advanced knowledge and demonstrated ability working with / recommending a variety of laboratory equipment/tools
  • Ability to work as part of and lead multiple teams
  • Exhibits leadership skill and ability, typically leads lower levels and/or indirect teams
  • Excellent computer skills
  • Excellent communications, problem-solving, analytical thinking skills
  • Sees broader picture, impact on multiple programs, teams and/or departments
  • Ability to meet multiple deadlines across a variety of projects/programs, with a high degree of accuracy and efficiency
  • Excellent project management skills
Responsibilities
  • Design formulations/processes for parenteral delivery of peptides/proteins to support preclinical and clinical studies (small molecule parenteral and oral drug product development experience is a positive differentiator)
  • Develop analytical methods for evaluation of various parenteral peptide/protein formulations (e.g, HPLC stability testing methods, SEC-MALS, DLS, isoelectric point, etc.)
  • Understanding of compendial methods of sterile drug product manufacturing (e.g, sterility, endotoxin, sub-visible particles, etc.)
  • Identify and manage CDMOs to assist with out-sourcing of manufacturing (compounding, sterile fill finish, etc) and release testing to support clinical studies
  • Perform person-in-plant support (business travel) at CDMO partner facilities in support of clinical trial manufacturing, as needed
  • Provide injectable formulation and peptide development training for other personnel to promote education of existing small molecule staff
  • Lead development of 1 or more of Neurocrine’s clinical assets
  • Perform feasibility studies of various formulations for company’s drug candidates and support form selection
  • Prepare study reports (e.g, summary of feasibility studies, formulation and process development, etc.)
  • Search and assess up-to-date scientific knowledge/information of various formulation approaches and maintain knowledge base of company’s interests
  • Support other activities of drug product development programs when needed
Desired Qualifications
  • Master's degree in Chemistry, Biochemistry, Biology, Chemical Engineering, or related field preferred and 6+ years of similar experience noted above
  • PharmD (preferred) and 4+ years of similar experience noted above
  • Small molecule parenteral and oral drug product development experience is a positive differentiator
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • Neurocrine's strategic collaboration with Takeda enhances drug development and commercialization.
  • The $500 million share repurchase program reflects strong capital allocation strategies.
  • CRENESSITY's launch in the US expands Neurocrine's market presence in rare diseases.

What critics are saying

  • Increased competition from companies like Sage Therapeutics and Biogen in neuroscience.
  • Potential challenges in osavampator's commercialization due to a competitive landscape.
  • Financial impact of share repurchase program may limit R&D investment.

What makes Neurocrine Biosciences unique

  • Neurocrine focuses on under-addressed neurological, neuroendocrine, and neuropsychiatric disorders.
  • CRENESSITY is the first non-steroidal treatment for classic congenital adrenal hyperplasia.
  • Neurocrine's osavampator is a potential first-in-class AMPA positive allosteric modulator.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

Company News

BioSpace
Mar 12th, 2025
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

SAN DIEGO, March 11, 2025 /PRNewswire/ - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025.

PR Newswire
Mar 11th, 2025
Neurocrine Biosciences To Present At The Stifel 2025 Virtual Cns Forum

SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer Eiry Roberts will present at the conference.The live webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.About Neurocrine BiosciencesNeurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders

PR Newswire
Feb 21st, 2025
Neurocrine Biosciences Board Of Directors Authorizes $500 Million Share Repurchase Program

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.William Rastetter, Chairman of the Board of Directors of Neurocrine Biosciences, said, "This authorization reflects our approach to capital allocation that balances driving sustained revenue growth through investing in our commercial products, INGREZZA and CRENESSITY, advancing our expanding R&D pipeline and returning capital to shareholders."Under the new authorization, repurchases may be made from time to time at management's discretion through a variety of methods, such as open-market transactions including pre-set trading plans, privately negotiated transactions, accelerated share repurchases, and other transactions in accordance with applicable securities laws.About Neurocrine BiosciencesNeurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life- changing treatments for patients with under-addressed neuropsychiatric, neurological, and neuroendocrine disorders. The company's diverse portfolio includes U.S

PR Newswire
Jan 27th, 2025
Neurocrine Biosciences Announces Amendment To Strategic Collaboration With Takeda To Develop And Commercialize Osavampator (Formerly Nbi-1065845/Tak-653)

- Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator- Takeda Reacquires Rights to Osavampator in JapanSAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights. Under the terms of the updated agreement, each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments."This streamlined collaboration structure allows Neurocrine to focus on bringing this important medicine to patients as quickly as possible," said Kyle Gano, Ph.D., Chief Executive Officer at Neurocrine Biosciences. "With the recent successful completion of our End-of-Phase 2 meeting with FDA for osavampator, we look forward to beginning the Phase 3 program in the first half of this year.""With its long-standing expertise developing therapies for serious psychiatric disorders, Neurocrine is the ideal partner to develop osavampator," said Sarah Sheikh, M.Sc., B.M., B.Ch, MRCP, Head, Neuroscience Therapeutic Area Unit and Head, Global Development at Takeda

PR Newswire
Jan 21st, 2025
Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today In The Journal Of Clinical Endocrinology Metabolism

SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM), sponsored by the company. The supplement, titled "Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime," contains eight review articles that provide a comprehensive look at the clinical, psychosocial, treatment-related and day-to-day challenges faced by individuals with classic CAH. JCEM is a leader in disseminating research that supports healthcare providers, patients and caregivers in advancing the understanding and management of various endocrinology conditions, such as CAH."Our understanding of the genetics, pathophysiology, and complications of CAH has exploded over the last 20 years," said Dr. Richard Auchus, M.D., Ph.D., Principal Investigator, Professor of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes at the University of Michigan